Short answer
ORTHOPEDIATRICS CORP (KIDS) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Upcoming investor and analyst presentations by OrthoPediatrics executives.
ORTHOPEDIATRICS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Upcoming investor and analyst presentations by OrthoPediatrics executives
- Exhibit 99.1 contains presentation materials that may shape near-term investor expectations
Item EX-99.1 · Exhibit EX-99.1
- 3Q26 revenue $72.7M, up 19%, with gross margin steady at 74%
- Net loss narrowed to $5.9M from $11.8M, while diluted loss improved to $0.25 from $0.50
- Adjusted EBITDA increased to $6.9M from $6.2M, supporting operating leverage despite continued investment
- FY2026 guidance: revenue $270.0M to $273.0M, 14% to 16% growth, adjusted EBITDA approximately $25.0M
- Balance sheet included $44.9M cash and investments versus $98.4M debt as of September 30, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ORTHOPEDIATRICS CORP 8-K filings
Get the next KIDS 8-K as it lands
Follow KIDS for push alerts, or ask the research agent what this filing means.